Given that plasma and tissue levels of AngII are significantly altered in hypertension [7,8,10,11,81] this source of RAS may provide a novel opportunity for precise therapeutic targeting of sympathetic nerves, to attenuate the effects of AngII within the myocardium [3,61,82,83]. The gene discussed is AGT; the disease is hypertensive disorder.